Manila Times Business
Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026
Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical developmentGhent, Belgium - June 15, 2026 - Confo Therapeutics, a clinical-stage biotechnology company advancing novel GPCR-directed medicines, today announced preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), at the Endocrine Society’s Annual Meeting (ENDO) 2026. The data support CFTX-2034 as a potential first-in
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
154 new apartment homes coming to Fairborn
1h ago
University of the Commonwealth Caribbean to build the Caribbean's first university smart city.
1h ago
HII Leads Successful DefenseTech LIVE Event, Advancing Speed, Integration, and Mission Driven Innovation
1h ago
SkyAI Confirms Receipt of Unsolicited, Non-Binding Proposal from Forward Industries
1h ago